Overview

• Experts at the ECFS meeting in Milan reported longer survival linked to CFTR modulators and warned that high prices still limit access to innovative drugs worldwide.
• Argentina’s national registry counted 1,888 people with cystic fibrosis through March 2025, a prevalence of roughly 1 in 6,700 births, with 80.2% younger than 26.
• A 21-year review from HIGA R. Rossi in La Plata found overall survival of 82% at five years, 72% at ten years, and 40% at twenty years among 124 adults.
• Dr. Ezequiel Baran said Gador’s locally produced triple therapy has demonstrated bioequivalence to the original drug with the same effectiveness, positioning it as a broader access option in Argentina.
• A three-center survey documented five recent pregnancies carried to term by women who remained on triple therapy without complications and with clinical stability.